AstraZeneca has completed the divestment of commercial rights to Atacand ( candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide ) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm). Financial considerations…